期刊文献+

乳酸左氧氟沙星片剂的健康人体药代动力学和相对生物利用度研究 被引量:3

Pharmacokinetics and Relative Bioavailablity of Levofloxacin Lactate Tablet in Chinese Healthy Volunteers
下载PDF
导出
摘要 目的:研究乳酸左旋氧氟沙星片剂的健康人体药代动力学和相对生物利用度。方法:18名健康受试者单次,交叉口服乳酸左旋氧氟沙星片200mg后,用HPLC-荧光法测定血浆中左氧氟沙星浓度,用BAPP2.0软件进行数据处理,计算药代动力学参数。结果:供试与参比制剂的药时曲线可用二室模型拟合,两者主要药代动力学参数Cmax分别为(2.92±0.60)μg/mL、(3.22±0.53)μg/mL,Tmax分别为(0.9±0.3)h、(0.9±0.3)h;t1/2分别为(7.27±1.02)h、(6.83±0.80)h;AUC0-24分别为(17.18±2.46)μg/(mL·h)、(17.19±2.55)μg/(mL·h)。乳酸左氧氟沙星片供试制剂的相对生物利用度为(100.3±9.4)%。结论:供试与参比制剂具有生物等效性。 Objective:To investigate the pharmacokinetics and relative bioavailability of levofloxacin lactate tablets and to evaluate its bioequivalence. Methods. A single oral dose 200mg of two levofloxacin lactate tablets was given to 18 healthy volunteers in a randomized cross-over study. The concentration of levofloxacin in plasma was determined by HPLC with fluorimetric detection. The pharmacokinetic parameters were calculated by BAPP 2. 0 software. Results:The concentrationtime curves after medication conformed to a two-compartment open model. The main pharmacokinetic parameters of the test tablets and reference tablets mL.(3.22 ± 0.53)μg/mL; Tmax(0.9 ±0. 3)h.0. 9±0. 3 were as follow: Cmax(2. 92±0. 60)μg/ h;t1/2 (7. 27±1.02)h; (6.83±0. 80)h; AUC0-24 (17. 18±2.46)μg/(mL · h),(17. 19±2. 55)μg/(mL · h);The relative bioavailability of the test tablets was (100. 3 ±9.4)%. Conclusion: The results demonstrated that the two levofloxacin lactate tablets were bioeouivalent.
出处 《实用临床医学(江西)》 CAS 2006年第4期1-3,5,共4页 Practical Clinical Medicine
关键词 乳酸左氧氟沙星 高效液相色谱荧光检测法 药代动力学 生物等效性 levofloxacin lactate high performance liquid chromatography-fluorescence detection method pharmacokinetics bioequivalent
  • 相关文献

参考文献6

二级参考文献15

  • 1黄圣凯,韩可勤.生物等效性评价的几种统计方法[J].中国临床药理学杂志,1993,9(1):43-46. 被引量:125
  • 2陆翔,方晓玲,蒋新国.氧氟沙星片人体生物利用度研究[J].中国药学杂志,1996,31(7):412-414. 被引量:1
  • 3李可欣,孙春华,曹国颖,缪竞智,傅得兴,杨湘霞.健康志愿者口服左氟沙星的体内药物动力学研究[J].中国抗生素杂志,1996,21(4):277-280. 被引量:15
  • 4Nakashima M, Uematsu T, Kanamaru M. et al. Phase Ⅰ study of levofloxacin (s)-(-)-ofloxacin[ J]. Jpn J Clin Pharmacol Ther,1992, 23(3) : 515.
  • 5Child J. Mortibody D. Andrews JM. et al. Open-label crossover study to determine the pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammation fluid[ J]. Antimicrob Agents Chemother, 1995, 39(10) : 2749.
  • 6中华人民共和国药典委员会,中国药典.2,1995年
  • 7Liang HR, Kays MB, Sowinski KM. Separation of levofloxacin,ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma [J]. J Chromatogr B, 2002, 772 (1) : 53-63.
  • 8Cheng FC, Tsai TR, Chen YF, et al. Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography [J]. J Chromatogr A, 2002, 961(1): 131-136.
  • 9Nickel U, Joukhadar C, Frossard M, et al. Simultaneous determination of levofloxacin and ciprofloxacin in microdialysates and plasma by high-performance liquid chromatography [J].Anal Chim Acta, 2002, 463: 199-206.
  • 10Bottcher S, von-Baum H, Hoppe-Tichy T, et al. An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum [J]. J Pharm Biomed Anal,2001, 25 (2) : 197-203.

共引文献72

同被引文献8

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部